FDA has approved Alunbrig or Brigatinib for first-line treatment of patients with ALK-positive metastatic non-small cell lung cancer, as detected by FDA-approved test. This approval has been based on phase III ALTA-1L trial. In this trial, treatment with brigatinib demonstrated a 51% reduction in risk of disease progression or death in comparison with crizotinib in patients